Chemotherapy in focus: a meta-analysis confronts immunotherapy in the treatment of advanced melanoma

2021 ◽  
pp. 103304
Author(s):  
Vitoria Diana Mateus de Almeida Gonçalves ◽  
Marcelo Ferrari de Almeida Camargo Filho ◽  
Tânia Zaleski ◽  
Rogério Rodrigues Vilas Boas ◽  
Elaine Rossi Ribeiro ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Advanced Melanoma

scholarly journals A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma

2017 ◽  
Vol 6 (6) ◽  
pp. 1143-1153 ◽  
Author(s):  
Joao Paulo da Silveira Nogueira Lima ◽  
Mina Georgieva ◽  
Benjamin Haaland ◽  
Gilberto de Lima Lopes
Keyword(s):  
Systematic Review ◽  
Targeted Therapy ◽  
Meta Analysis ◽  
Advanced Melanoma

scholarly journals Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors

2018 ◽  
Vol 2018 ◽  
pp. 1-13 ◽  
Author(s):  
Sunil Badami ◽  
Sunil Upadhaya ◽  
Ravi Kanth Velagapudi ◽  
Pushyami Mikkilineni ◽  
Ranju Kunwor ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Random Effect ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Melanoma ◽  
Cochrane Library ◽  
Molecular Characteristics ◽  
Significant Heterogeneity

Background. We performed meta-analysis to gather more evidence regarding clinical-molecular subgroups associated with better overall survival (OS) in advanced melanoma treated with checkpoint inhibitors. Materials and Methods. We performed a systematic search of PubMed, Scopus, Cochrane Library, and clinical trial.gov. Randomized clinical trials that compared a checkpoint inhibitor (nivolumab or pembrolizumab) with investigator choice chemotherapy or ipilimumab were included in our study. Hazard ratios (HR) and confidence interval (CI) were calculated for progression-free survival (PFS) and OS for each subgroup using generic inverse model along with the random effect method. Results. A total of 6 clinical trials were eligible for the meta-analysis. OS was prolonged in wild BRAF subgroup (HR 0.65, 95% CI 0.49-0.85, p 0.002), Programmed cell death subgroup (PD-1+) (HR 0.57, 95% CI 0.41-0.80, p 0.001), and high lactate dehydrogenase (LDH) level subgroup (HR 0.60, 95% CI 0.38-0.95, p 0.03). Similarly, we found increased OS in eastern cooperative oncology group (ECOG) 1, males and age >65 years subgroups. Conclusions. Checkpoint inhibitors significantly increased OS in patients with wild BRAF, positive PD-1, and high LDH. However, results should be interpreted keeping in mind associated significant heterogeneity. The results of this study should help in designing future clinical trials.

Immune related adverse events (irAE) of mono-, combination, and sequential therapy regimens of ipilimumab (IPI), nivolumab (NIV), and pembrolizumab (PEM) for advanced melanoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e21011-e21011
Author(s):  
Abdulaali Almutairi ◽  
Ali McBride ◽  
Srinath Sundararajan ◽  
Ivo Abraham
Keyword(s):  
Clinical Trials ◽  
Meta Analysis ◽  
Phase 1 ◽  
Random Effect ◽  
Sequential Therapy ◽  
Incidence Rates ◽  
Advanced Melanoma ◽  
Regulatory Agencies ◽  
Regulatory Documents ◽  
Grade 3

e21011 Background: The immunotherapy agents IPI, NIV, and PEM have transformed the management of advanced melanoma but are associated with irAEs. We estimated the incidence of irAEs as observed in clinical trials of mono, combination , and sequential regimens of these agents in the advanced melanoma setting. Methods: We searched the Medline, Embase, and Cochrane databases; clinicaltrials.gov; and websites of regulatory agencies in USA, Europe, Australia, and Japan for phase 1-3 trials of IPI, NIV, and PEM in advanced melanoma. Random effect meta-analysis was utilized to estimate the incidence of irAEs (expressed as % with 95%CI) for all agents in mono-, combination, and sequential regimens. Results: 56 reports (32 published articles, 7 updates, 15 results published on clinicaltrials.gov and 2 regulatory documents) of 37 trials and relating unique and independent irAE data were included in the analysis. See Table. Conclusions: IPI mono had higher incidence rates of all grade and ≥ grade 3 hypophysitis and colitis but lower rates of all grade hypothyroidism, pneumonitis, and vitiligo than NIV or PEM mono. Combination and sequential regimens had higher irAE incidence rates compared to monotherapies except for grade ≥3 hypophysitis in PEM+IPI and NIV→IPI, and grade ≥3 vitiligo as well as all grade colitis and hypophysitis in IPI →NIV. Table. Incidence rates of select irAEs expressed as % with 95%CI (‡ all grade; * ≥ grade 3). [Table: see text]

The efficacy and safety of the combination of anti-BRAF agent and MEK inhibitor in advanced melanoma patients with BRAF V600 mutation: A meta-analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20006-e20006
Author(s):  
Changqing Xie ◽  
Basem Mourad Labib Mishriky ◽  
Phillip Chae ◽  
Prashanti Atluri
Keyword(s):  
Meta Analysis ◽  
Mek Inhibitor ◽  
Advanced Melanoma ◽  
Efficacy And Safety ◽  
Melanoma Patients ◽  
Braf V600 Mutation

Efficacy of immunotherapy in advanced melanoma: A network meta-analysis.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e21033-e21033 ◽  
Author(s):  
Belal Firwana ◽  
Mohamad Bassam Sonbol ◽  
Shebli Atrash ◽  
M. Hassan Murad ◽  
Issam Makhoul ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Advanced Melanoma

scholarly journals A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

2019 ◽  
Vol 123 ◽  
pp. 58-71 ◽  
Author(s):  
Margreet G. Franken ◽  
Brenda Leeneman ◽  
Maria Gheorghe ◽  
Carin A. Uyl-de Groot ◽  
John B.A.G. Haanen ◽  
...  
Keyword(s):  
Literature Review ◽  
Systematic Literature Review ◽  
Meta Analysis ◽  
Advanced Melanoma ◽  
Safety Outcomes
Sign in / Sign up

Export Citation Format

Share Document